Jean‐Baptiste Bachet

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text

Medicine, Oncology, Pharmacology +13

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Pascal Hammel, Mohamed Hebbar et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +14

<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

Astrid Lièvre, Jean‐Baptiste Bachet, Delphine Le Corre et al. · Cancer Research · 2006 · 2.2K citations

Medicine, Oncology, Pharmacology +17

<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Astrid Lièvre, Jean‐Baptiste Bachet, Valérie Boige et al. · Journal of Clinical Oncology · 2008 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne et al. · The Lancet Oncology · 2021 · 1.3K citations

Medicine, Oncology, Surgery +17